Vizsgálati helyszín
UCLA Hematology-Oncology - Santa Monica
Santa Monica, California 90404, Egyesült ÁllamokMég nincs intézményhez kötve
- 19futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis7 vizsgálat
- 1. fázis6 vizsgálat
- 1/2. fázis5 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Toboroz14 vizsgálat
- Fut, nem toboroz4 vizsgálat
- Leállították3 vizsgálat
- Lezárult2 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Pfizer11 vizsgálat
- Seagen, a wholly owned subsidiary of Pfizer4 vizsgálat
- Bristol-Myers Squibb1 vizsgálat
- CatalYm GmbH1 vizsgálat
- Celcuity Inc1 vizsgálat
- és még 6
Futó vizsgálatok
Toboroz
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892· 2/3. fázis· Pfizer· Forrás
Toboroz
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459· 2. fázis· CatalYm GmbH· Forrás
Contact: Richard Finn, MD
Toboroz
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· 1/2. fázis· Pfizer· Forrás
Toboroz
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· 2/3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499· 1. fázis· Pfizer· Forrás
Toboroz
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT06607458· 2. fázis· Delcath Systems Inc.· Forrás
Contact: Matthew Cooney, MD
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Edward Garon, Site 0111
Toboroz
SW-682 in Advanced Solid Tumors
NCT06251310· 1. fázis· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Forrás
Contact: Arun S Singh, MD (principal investigator)
Toboroz
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741· 1/2. fázis· DualityBio Inc.· Forrás
Contact: Aaron E. Lisberg, MD
Toboroz
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
NCT05948865· 1. fázis· Conjupro Biotherapeutics, Inc.· Forrás
Contact: Lee S. Rosen, MD (principal investigator)
Fut, nem toboroz
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· 3. fázis· Celcuity Inc· Forrás
Toboroz
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132· 1/2. fázis· Synthekine· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek